{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:27Z","timestamp":1792099647032,"version":"4.4.0"},"reference-count":46,"publisher":"Pacini Editore","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Otorhinolaryngol Ital"],"DOI":"10.14639\/0392-100x-n2762","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T08:30:58Z","timestamp":1709109058000},"page":"1-12","source":"Crossref","is-referenced-by-count":17,"title":["Measuring financial toxicity in head and neck cancer: a systematic review"],"prefix":"10.14639","volume":"44","author":[{"given":"Elisa","family":"Raggini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mattavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zigliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20340","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"10.14639\/0392-100X-N2762_ref1","unstructured":"Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 2013;27:80-149."},{"key":"10.14639\/0392-100X-N2762_ref2","doi-asserted-by":"crossref","unstructured":"Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience. Oncologist 2013;18:381-390. https:\/\/doi.org\/10.1634\/theoncologist.2012-0279","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"10.14639\/0392-100X-N2762_ref3","doi-asserted-by":"crossref","unstructured":"Witte J, Mehlis K, Surmann B, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol 2019;30:1061-1070. https:\/\/doi.org\/10.1093\/annonc\/mdz140","DOI":"10.1093\/annonc\/mdz140"},{"key":"10.14639\/0392-100X-N2762_ref4","doi-asserted-by":"crossref","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018;68:153-165. https:\/\/doi.org\/10.3322\/caac.21443","DOI":"10.3322\/caac.21443"},{"key":"10.14639\/0392-100X-N2762_ref5","doi-asserted-by":"crossref","unstructured":"Ma SJ, Iovoli AJ, Attwood K, et al. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy. Oral Oncol 2021;115:105196. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105196","DOI":"10.1016\/j.oraloncology.2021.105196"},{"key":"10.14639\/0392-100X-N2762_ref6","doi-asserted-by":"crossref","unstructured":"Qiao G, Chen M, Bucsek MJ, et al. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front Immunol 2018;9:164. https:\/\/doi.org\/10.3389\/fimmu.2018.00164","DOI":"10.3389\/fimmu.2018.00164"},{"key":"10.14639\/0392-100X-N2762_ref7","doi-asserted-by":"crossref","unstructured":"Hueniken K, Douglas CM, Jethwa AR, et al. Measuring financial toxicity incurred after treatment of head and neck cancer: development and validation of the Financial Index of Toxicity questionnaire. Cancer 2020;126:4042-4050. https:\/\/doi.org\/10.1002\/cncr.33032","DOI":"10.1002\/cncr.33032"},{"key":"10.14639\/0392-100X-N2762_ref8","doi-asserted-by":"crossref","unstructured":"de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST): measuring financial toxicity. Cancer 2017;123:476-484. https:\/\/doi.org\/10.1002\/cncr.3036","DOI":"10.1002\/cncr.30369"},{"key":"10.14639\/0392-100X-N2762_ref9","doi-asserted-by":"crossref","unstructured":"Dar MA, Chauhan R, Murti K, et al. Development and validation of Subjective Financial Distress Questionnaire (SFDQ): a patient reported outcome measure for assessment of financial toxicity among radiation oncology patients. Front Oncol 2022;11:819313. https:\/\/doi.org\/10.3389\/fonc.2021.819313","DOI":"10.3389\/fonc.2021.819313"},{"key":"10.14639\/0392-100X-N2762_ref10","doi-asserted-by":"crossref","unstructured":"Riva S, Arenare L, Di Maio M, et al. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open 2021;11:E049128. https:\/\/doi.org\/10.1136\/bmjopen-2021-049128","DOI":"10.1136\/bmjopen-2021-049128"},{"key":"10.14639\/0392-100X-N2762_ref11","doi-asserted-by":"crossref","unstructured":"Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. JNCI J Natl Cancer Inst 2016;109:djw205. https:\/\/doi.org\/10.1093\/jnci\/djw205","DOI":"10.1093\/jnci\/djw205"},{"key":"10.14639\/0392-100X-N2762_ref12","doi-asserted-by":"crossref","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;Mar 29;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","DOI":"10.1136\/bmj.n160"},{"key":"10.14639\/0392-100X-N2762_ref13","unstructured":"Ottawa Hospital Research Institute. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed September 20, 2023."},{"key":"10.14639\/0392-100X-N2762_ref14","doi-asserted-by":"crossref","unstructured":"B\u00f6hm K, Schmid A, G\u00f6tze R, et al. Five types of OECD healthcare systems: empirical results of a deductive classification. Health Policy. 2013;113:258-269. https:\/\/doi.org\/10.1016\/j.healthpol.2013.09.003","DOI":"10.1016\/j.healthpol.2013.09.003"},{"key":"10.14639\/0392-100X-N2762_ref15","doi-asserted-by":"crossref","unstructured":"Massa ST, Rohde RL, Mckinstry C, et al. An assessment of patient burdens from head and neck cancer survivorship care. Oral Oncol 2018;82:115-121. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.04.024","DOI":"10.1016\/j.oraloncology.2018.04.024"},{"key":"10.14639\/0392-100X-N2762_ref16","doi-asserted-by":"crossref","unstructured":"Dar MA, Chauhan R, Sharma KK, et al. Assessing the reliability and validity of comprehensive score for financial toxicity (COST) among radiation oncology patients in India: a cross-sectional pilot study. Ecancermedicalscience 2021;15:1219. https:\/\/doi.org\/10.3332\/ecancer.2021.1219","DOI":"10.3332\/ecancer.2021.1219"},{"key":"10.14639\/0392-100X-N2762_ref17","doi-asserted-by":"crossref","unstructured":"Lenze NR, Bensen JT, Farnan L, et al. Association of self-reported financial burden with quality of life and oncologic outcomes in head and neck cancer. Head Neck 2022;44:412-419. https:\/\/doi.org\/10.1002\/hed.26934","DOI":"10.1002\/hed.26934"},{"key":"10.14639\/0392-100X-N2762_ref18","doi-asserted-by":"crossref","unstructured":"O\u2019Brien KM, Timmons A, Butow P, et al. Associations between neighbourhood support and financial burden with unmet needs of head and neck cancer survivors. Oral Oncol 2017;65:57-64. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.12.019","DOI":"10.1016\/j.oraloncology.2016.12.019"},{"key":"10.14639\/0392-100X-N2762_ref19","doi-asserted-by":"crossref","unstructured":"Lu L, O\u2019Sullivan E, Sharp L. Cancer-related financial hardship among head and neck cancer survivors: risk factors and associations with health-related quality of life. Psychooncology 2019;28:863-871. https:\/\/doi.org\/10.1002\/pon.5034","DOI":"10.1002\/pon.5034"},{"key":"10.14639\/0392-100X-N2762_ref20","doi-asserted-by":"crossref","unstructured":"Massa ST, Osazuwa-Peters N, Adjei Boakye E, et al. Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors. JAMA Otolaryngol Head Neck Surg 2019;145:239-249. https:\/\/doi.org\/10.1001\/jamaoto.2018.3982","DOI":"10.1001\/jamaoto.2018.3982"},{"key":"10.14639\/0392-100X-N2762_ref21","doi-asserted-by":"crossref","unstructured":"de Souza JA, Kung S, O\u2019Connor J, et al. Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer. J Oncol Pract 2017;13:E310-E318. https:\/\/doi.org\/10.1200\/JOP.2016.016337","DOI":"10.1200\/JOP.2016.016337"},{"key":"10.14639\/0392-100X-N2762_ref22","doi-asserted-by":"crossref","unstructured":"Chauhan AS, Prinja S, Ghoshal S, et al. Economic burden of head and neck cancer treatment in North India. Asian Pac J Cancer Prev APJCP 2019;20:403-409. https:\/\/doi.org\/10.31557\/APJCP.2019.20.2.403","DOI":"10.31557\/APJCP.2019.20.2.403"},{"key":"10.14639\/0392-100X-N2762_ref23","doi-asserted-by":"crossref","unstructured":"Amarasinghe H, Jayasinghe RD, Dharmagunawardene D, et al. Economic burden of managing oral cancer patients in Sri Lanka: a cross-sectional hospital \u2013 based costing study. BMJ Open 2019;9:E027661. https:\/\/doi.org\/10.1136\/bmjopen-2018-027661","DOI":"10.1136\/bmjopen-2018-027661"},{"key":"10.14639\/0392-100X-N2762_ref24","doi-asserted-by":"crossref","unstructured":"Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among thyroid cancer survivors. Surgery 2020;167:631-637. https:\/\/doi.org\/10.1016\/j.surg.2019.11.014","DOI":"10.1016\/j.surg.2019.11.014"},{"key":"10.14639\/0392-100X-N2762_ref25","doi-asserted-by":"crossref","unstructured":"Barrows CE, Belle JM, Fleishman A, et al. Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors. Surgery 2020;167:378-384. https:\/\/doi.org\/10.1016\/j.surg.2019.09.010","DOI":"10.1016\/j.surg.2019.09.010"},{"key":"10.14639\/0392-100X-N2762_ref26","doi-asserted-by":"crossref","unstructured":"Farrugia M, Yu H, Ma SJ, et al. Financial counseling is associated with reduced financial difficulty scores in head and neck cancer patients treated with radiation therapy. Cancers 2021;13:2516. https:\/\/doi.org\/10.3390\/cancers13112516","DOI":"10.3390\/cancers13112516"},{"key":"10.14639\/0392-100X-N2762_ref27","doi-asserted-by":"crossref","unstructured":"Chen DW, Reyes-Gastelum D, Veenstra CM, et al. Financial hardship among hispanic women with thyroid cancer. Thyroid 2021;31:752-759. https:\/\/doi.org\/10.1089\/thy.2020.0497","DOI":"10.1089\/thy.2020.0497"},{"key":"10.14639\/0392-100X-N2762_ref28","doi-asserted-by":"crossref","unstructured":"Mott NM, Mierzwa ML, Casper KA, et al. Financial hardship in patients with head and neck cancer. JCO Oncol Pract 2022;18:E925-E937. https:\/\/doi.org\/10.1200\/OP.21.00683","DOI":"10.1200\/OP.21.00683"},{"key":"10.14639\/0392-100X-N2762_ref29","doi-asserted-by":"crossref","unstructured":"Thaduri A, Garg PK, Malhotra M, et al. Financial toxicity and mental well-being of the oral cancer survivors residing in a developing country in the era of COVID 19 pandemic \u2013 a cross-sectional study. Psychooncology 2023;32:58-67. https:\/\/doi.og\/10.1002\/pon.6030","DOI":"10.1002\/pon.6030"},{"key":"10.14639\/0392-100X-N2762_ref30","doi-asserted-by":"crossref","unstructured":"Khan MN, Hueniken K, Manojlovic-Kolarski M, et al. Out-of-pocket costs associated with head and neck cancer treatment. Cancer Rep 2021;5:E1528. https:\/\/doi.org\/10.1002\/cnr2.1528","DOI":"10.1002\/cnr2.1528"},{"key":"10.14639\/0392-100X-N2762_ref31","doi-asserted-by":"crossref","unstructured":"Broekhuis JM, Li C, Chen HW, et al. Patient-reported financial burden in thyroid cancer. J Surg Res 2021;266:160-167. https:\/\/doi.org\/10.1016\/j.jss.2021.03.051","DOI":"10.1016\/j.jss.2021.03.051"},{"key":"10.14639\/0392-100X-N2762_ref32","doi-asserted-by":"crossref","unstructured":"Beeler WH, Bellile EL, Casper KA, et al. Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncol 2020;101:104521. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104521","DOI":"10.1016\/j.oraloncology.2019.104521"},{"key":"10.14639\/0392-100X-N2762_ref33","doi-asserted-by":"crossref","unstructured":"Jella TK, Cwalina TB, Sachdev R, et al. Prevalence, trends, and demographic characteristics associated with self-reported financial stress among head and neck cancer patients in the United States of America. Am J Otolaryngol 2021;42:103154. https:\/\/doi.org\/10.1016\/j.amjoto.2021.103154","DOI":"10.1016\/j.amjoto.2021.103154"},{"key":"10.14639\/0392-100X-N2762_ref34","doi-asserted-by":"crossref","unstructured":"Baddour K, Fadel M, Zhao M, et al. The cost of cure: examining objective and subjective financial toxicity in head and neck cancer survivors. Head Neck 2021;43:3062-3075. https:\/\/doi.org\/10.1002\/hed.26801","DOI":"10.1002\/hed.26801"},{"key":"10.14639\/0392-100X-N2762_ref35","doi-asserted-by":"crossref","unstructured":"Mady LJ, Lyu L, Owoc MS, et al. Understanding financial toxicity in head and neck cancer survivors. Oral Oncol 2019;95:187-193. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.06.023","DOI":"10.1016\/j.oraloncology.2019.06.023"},{"key":"10.14639\/0392-100X-N2762_ref36","doi-asserted-by":"crossref","unstructured":"Egestad H, Nieder C. Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. Int J Circumpolar Health 2015;74:26686. https:\/\/doi.org\/10.3402\/ijch.v74.26686","DOI":"10.3402\/ijch.v74.26686"},{"key":"10.14639\/0392-100X-N2762_ref37","doi-asserted-by":"crossref","unstructured":"Rogers SN, Harvey-Woodworth CN, Hare J, et al. Patients\u2019 perception of the financial impact of head and neck cancer and the relationship to health related quality of life. Br J Oral Maxillofac Surg 2012;50:410-416. https:\/\/doi.org\/10.1016\/j.bjoms.2011.07.026","DOI":"10.1016\/j.bjoms.2011.07.026"},{"key":"10.14639\/0392-100X-N2762_ref38","doi-asserted-by":"crossref","unstructured":"Rogers SN, Harvey-Woodworth CN, Lowe D. Patients\u2019 perspective of financial benefits following head and neck cancer in Merseyside and Cheshire. Br J Oral Maxillofac Surg 2012;50:404-409. https:\/\/doi.org\/10.1016\/j.bjoms.2011.07.020","DOI":"10.1016\/j.bjoms.2011.07.020"},{"key":"10.14639\/0392-100X-N2762_ref39","doi-asserted-by":"crossref","unstructured":"Khera N, Chang YH, Hashmi S, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1375-1381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.011","DOI":"10.1016\/j.bbmt.2014.05.011"},{"key":"10.14639\/0392-100X-N2762_ref40","doi-asserted-by":"crossref","unstructured":"Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer population. Oral Maxillofac Surg Clin N Am 2018;30:381-395. https:\/\/doi.org\/10.1016\/j.coms.2018.06.001","DOI":"10.1016\/j.coms.2018.06.001"},{"key":"10.14639\/0392-100X-N2762_ref41","doi-asserted-by":"crossref","unstructured":"Buckwalter AE. Patient-reported factors associated with discontinuing employment following head and neck cancer treatment. Arch Otolaryngol Head Neck Surg 2007;133:464. https:\/\/doi.org\/10.1001\/archotol.133.5.464","DOI":"10.1001\/archotol.133.5.464"},{"key":"10.14639\/0392-100X-N2762_ref42","doi-asserted-by":"crossref","unstructured":"Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-1573. https:\/\/doi.org\/10.1093\/annonc\/mdv249","DOI":"10.1093\/annonc\/mdv249"},{"key":"10.14639\/0392-100X-N2762_ref43","doi-asserted-by":"crossref","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-2577. https:\/\/doi.org\/10.1200\/JCO.2015.61.6706","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"10.14639\/0392-100X-N2762_ref44","doi-asserted-by":"crossref","unstructured":"Henrikson NB, Tuzzio L, Loggers ET, et al. Patient and oncologist discussions about cancer care costs. Support Care Cancer 2014;22:961-967. https:\/\/doi.org\/10.1007\/s00520-013-2050-x","DOI":"10.1007\/s00520-013-2050-x"},{"key":"10.14639\/0392-100X-N2762_ref45","doi-asserted-by":"crossref","unstructured":"Bjordal K, Ahiner-Elmqvist M, Tolleson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) Questionnaire module to be used in quality of life assessments in head and neck cancer patients. Acta Oncologica 1994;33:879-885. https:\/\/doi.org\/10.3109\/02841869409098450","DOI":"10.3109\/02841869409098450"},{"key":"10.14639\/0392-100X-N2762_ref46","unstructured":"Marshall GN, Hays RD. The Patient Satisfaction Questionnaire Short-Form (PSQ-18). Santa Monica CA: RAND, 1994."}],"container-title":["Acta Otorhinolaryngologica Italica"],"original-title":[],"link":[{"URL":"https:\/\/www.actaitalica.it\/article\/view\/2762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T03:22:46Z","timestamp":1729653766000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.actaitalica.it\/article\/view\/2762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.14639\/0392-100x-n2762","relation":{},"ISSN":["1827-675X"],"issn-type":[{"value":"1827-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"article-number":"1"}}